Stock 0QF MODERNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Moderna, Inc. BOERSE MUENCHEN

Equities

0QF

US60770K1079

Real-time BOERSE MUENCHEN
Other stock markets
 01:13:52 2024-06-27 pm EDT 		5-day change 1st Jan Change
112.8 EUR -1.79% Intraday chart for Moderna, Inc. -8.17% +25.67%
01:57pm GSK Shares Slump After CDC Narrows Age Recommendation for RSV Shots DJ
01:44pm CDC Updates RSV Shot Recommendation Among the Elderly; Vaccine Makers Mixed Pre-Bell MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
MODERNA, INC. Stock Moderna, Inc.
+25.67% 46.93B -
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.08B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.35% 38.48B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+27.78% 31.01B
B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.28% 25.88B
B-
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+35.89% 12.53B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.53% 11.36B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.46% 10.65B
C+
QIAGEN N.V. Stock Qiagen N.V.
-8.19% 9.04B
A
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. 0QF Stock
  5. Ratings Moderna, Inc.